The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 505-512

  Krysiak, Robert ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cytokines; hypercholesterolemia; hypolipidemic agents; monocytes; systemic inflammation

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE CYTOKINE RELEASE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MONOCYTES; RISK FACTORS; SIMVASTATIN; TIME FACTORS;

EID: 79955005698     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318211703b     Document Type: Article

References (33)

1. Davidson H. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009;11:67-70.
2. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med. 2008;47:1165-1170.
3. Bays HE, Neff D, Tomassini JE, et al. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008;6:447-470.
4. Yagi S, Akaike M, Aihara K, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. JAtheroscler Thromb. 2010;17:173-180.
5. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010;33: 1134-1139.
6. Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr. 2010;2:34.
7. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism. 2010;59:921-926.
8. Gupta M, Szmitko PE, Tsigoulis M, et al. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. J Cardiovasc Pharmacol. 2010;56:241-245.
9. Alvarez-Sala LA, Cachofeiro V, Masana L, et al. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther. 2008;30:84-97. (Pubitemid 351834727)
10. Seedorf U, Engel T, Lueken A, et al. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun. 2004;320:1337-1341. (Pubitemid 38916690)
11. Orsó E, Werner T, Wolf Z, et al. Ezetimib influences the expression of raft-associated antigens in human monocytes. CytometryA. 2006;69:206-208.
12. Gómez-Garre D, Muñoz-Pacheco P, González-Rubio ML, et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol. 2009;156:1218-1227
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
14. Okopień B, Kowalski J, Krysiak R, et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep. 2005;57:367-372. (Pubitemid 41030697)
15. Okopien B, Krysiak R, Haberka M, et al. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2005;45:314-320. (Pubitemid 40411286)
16. Okopień B, Krysiak R, Kowalski J, et al. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol. 2005;46:377-386. (Pubitemid 41262842)
17. Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. NEngl J Med. 2008;358:1431-1443. (Pubitemid 351482735)
18. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N EnglJ Med. 2008;359:1343-1356.
19. Kher N, Marsh JD. Pathobiology of atherosclerosis\a brief review. Semin Thromb Hemost. 2004;30:665-672.
20. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
21. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009;7(suppl 1):328-331.
22. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol. 2009;7:234-243.
23. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006;98:P2-P8.
24. Ridker PM. Inflammatory biomarkers and risks ofmyocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(2):S253-S259.
25. Krysiak R, Okopien B. The effect of simvastatin on lymphocyte secretory function in patients with impaired fasting glucose. J Cardiovasc Pharmacol. 2010;56:491-497.
26. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study Am Heart J. 2005;149:464-473. (Pubitemid 40585409)
27. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134. (Pubitemid 36005898)
28. Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin EndocrinolDiabetes Obes. 2009;16:183-188.
29. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007;59:483-499.
30. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
31. Sabatine MS, Wiviott SD, Morrow DA. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation. 2004;110(suppl):S834.
32. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. JAtheroscler Thromb. 2008;15:269-275.
33. Montecucco F, Mach F Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab. 2009; 23:389-400.